ACM
LRMR icon

Altium Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Altium Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-396,000
Closed -$1.53M – 50
2024
Q4 		$1.53M Buy
396,000
+200,000
+102% +$1.32M 0.43% 51
2024
Q3 		$1.28M Hold
196,000
– – 0.38% 47
2024
Q2 		$1.42M Buy
+196,000
New +$1.5M 0.58% 30

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Altium Capital Management's LRMR Position: Q2 2025 in Review

Altium Capital Management sold out of Larimar Therapeutics (LRMR) in Q2 2025, closing a stake of 273,204 shares — an estimated $587K sold.

Altium Capital Management first reported a position in LRMR in Q4 2020 and held it in 8 quarters. The position peaked at $5.28M in Q1 2024. 116 funds tracked by Wall St. Rank hold LRMR as of Q2 2025.

  • Altium Capital Management reported no remaining Larimar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Altium Capital Management sold 273,204 Larimar Therapeutics shares in Q2 2025, an estimated $587K.
  • Altium Capital Management first reported a position in Larimar Therapeutics in Q4 2020 and held it in 8 quarters.
  • Altium Capital Management's Larimar Therapeutics position peaked at $5.28M in Q1 2024.
  • 116 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2025.

Based on Altium Capital Management's 13F filing for Q2 2025.